David Barrera

Results of a phase 2 study of bortezomib in patients with relapsed or refractory indolent lymphoma

Nicholas Di Bella, Raymond Taetle, Kathryn S. Kolibaba et al. · Blood · 2009 · 77 citations · Full text

Medicine, Hematology, Oncology +13

Phase III Trial of Cetuximab, Bevacizumab, and 5-Fluorouracil/Leucovorin vs. FOLFOX-Bevacizumab in Colorectal Cancer

Leonard B. Saltz, Suprith Badarinath, Shaker R. Dakhil et al. · Clinical Colorectal Cancer · 2011 · 69 citations

Medicine, Oncology, Pharmacology +11

Phase II Trial of Nanoparticle Albumin-Bound Paclitaxel, Carboplatin, and Bevacizumab in First-line Patients with Advanced Nonsquamous Non-small Cell Lung Cancer

Craig H. Reynolds, David Barrera, Robert M. Jotte et al. · Journal of Thoracic Oncology · 2009 · 58 citations · Full text

Medicine, Oncology, Pharmacology +16

Randomized, Phase II Trial of Pemetrexed and Carboplatin with or without Enzastaurin versus Docetaxel and Carboplatin as First-Line Treatment of Patients with Stage IIIB/IV Non-small Cell Lung Cancer

Mark A. Socinski, Robert N. Raju, Thomas E. Stinchcombe et al. · Journal of Thoracic Oncology · 2010 · 34 citations · Full text

Medicine, Oncology, Pharmacology +13

An open-label, phase II trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel), carboplatin, and bevacizumab in first-line patients with advanced non-squamous non-small cell lung cancer (NSCLC)

C. Reynolds, David Barrera, Dennis Vu et al. · Journal of Clinical Oncology · 2007 · 15 citations

Medicine, Oncology, Pharmacology +14